Guggenheim analyst Yatin Suneja lowered the firm’s price target on Immunovant (IMVT) to $41 from $44 and keeps a Buy rating on the shares following the company’s recent $550M equity raise. The firm cites a higher share count and modest dilution, partially offset by an extended cash runway and strengthened balance sheet, for its adjusted target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant Raises $550 Million Through Stock Offering
- Immunovant’s Strategic Advancements and Promising Pipeline Drive Buy Rating
- Immunovant Announces $550 Million Stock Offering
- Immunovant Restructures R&D Leadership with CMO Departure
- Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength